In this issue:
Erlotinib improves PFS in EGFR-mutant patients
Improving pathological staging accuracy
Strategy improves survival in stage 3 NSCLC
Markers of prognosis in resected stage 1B NSCLC
Carboplatin equivalent to a higher dose of cisplatin in advanced NSCLC
Pemetrexed in advanced non-squamous NSCLC
Cetuximab and CT: OS benefit in advanced NSCLC
Who needs mediastinoscopy after endosonography?
Danish Lung Cancer Screening Trial: 5-year data
Personalised MetMAb promising in NSCLC
Afatinib + cetuximab in NSCLC progressing on erlotinib/gefitinib
Preoperative chemotherapy: benefits in NSCLC
Please login below to download this issue (PDF)